Intersouth Partners
Intersouth Partners is a Durham, North Carolina–based venture capital firm founded in 1985 that concentrates on seed and early-stage investments in technology and life sciences. It seeks to be a lead or co-lead investor, often participating in the first institutional round with initial investments in the range of several hundred thousand to several million dollars and pursuing a total investment across rounds around ten to twelve million dollars. The firm emphasizes equity investments and typically seeks a board seat on portfolio companies, aiming to support growth in sectors such as software, semiconductors, communications, digital media, clean technology, security, medical devices, biopharmaceuticals, agricultural biotechnology, and biomaterials. Its geographic focus centers on the Southeast, including the Research Triangle area, Washington, DC, Atlanta, and the broader corridor from Baltimore to Florida. The firm is known for its active engagement and long-standing experience in building early-stage technology and life sciences companies.
Top Stages
https://crunchbase.com/organization/***
https://linkedin.com/company/***
Past deals in Maryland
CSA Medical
Series D in 2024
CSA Medical, Inc., established in 1993 and headquartered in Baltimore, Maryland, specializes in the development and manufacturing of spray cryotherapy medical devices. Its primary product, truFreeze, utilizes cold liquid nitrogen to destroy unwanted tissue across dermatology, gynecology, and general surgery fields while promoting healthy tissue regrowth. CSA Medical also offers the Rapid AV Spray Kit to enhance truFreeze's efficiency. The company operates a research and development facility in Lexington, Massachusetts.
CSA Medical
Venture Round in 2019
CSA Medical, Inc., established in 1993 and headquartered in Baltimore, Maryland, specializes in the development and manufacturing of spray cryotherapy medical devices. Its primary product, truFreeze, utilizes cold liquid nitrogen to destroy unwanted tissue across dermatology, gynecology, and general surgery fields while promoting healthy tissue regrowth. CSA Medical also offers the Rapid AV Spray Kit to enhance truFreeze's efficiency. The company operates a research and development facility in Lexington, Massachusetts.
CSA Medical
Series C in 2013
CSA Medical, Inc., established in 1993 and headquartered in Baltimore, Maryland, specializes in the development and manufacturing of spray cryotherapy medical devices. Its primary product, truFreeze, utilizes cold liquid nitrogen to destroy unwanted tissue across dermatology, gynecology, and general surgery fields while promoting healthy tissue regrowth. CSA Medical also offers the Rapid AV Spray Kit to enhance truFreeze's efficiency. The company operates a research and development facility in Lexington, Massachusetts.
CSA Medical
Series B in 2011
CSA Medical, Inc., established in 1993 and headquartered in Baltimore, Maryland, specializes in the development and manufacturing of spray cryotherapy medical devices. Its primary product, truFreeze, utilizes cold liquid nitrogen to destroy unwanted tissue across dermatology, gynecology, and general surgery fields while promoting healthy tissue regrowth. CSA Medical also offers the Rapid AV Spray Kit to enhance truFreeze's efficiency. The company operates a research and development facility in Lexington, Massachusetts.
MaxCyte
Series B in 2004
MaxCyte is a global cell engineering company that provides enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics and to support cell-based research. It develops and sells automated transfection systems based on flow electroporation, such as STX, VLX, and GT, for scalable, non-viral engineering of primary cells, stem cells, and cell lines, alongside single-use disposable processing assemblies, proprietary electroporation buffers, and ExPERT instruments and consumables, as well as insourcing services. The company pursues CARMA, a proprietary non-viral, messenger RNA-based approach to redirect immune cells, including CAR-T and TCR-engineered therapies. Revenue is generated from the sale and licensing of instruments and technology to drug developers and biopharmaceutical companies. Founded in 1998 and headquartered in Gaithersburg, Maryland.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.